Celldex Therapeutics (CLDX) FCF Margin (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly FCF Margin of 448260.0% for Q1 2026, down 44039856.0% year-over-year from N/an in Q1 2025, and down 731.56% quarter-over-quarter from 53905.79% in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) FCF Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' FCF Margin history runs 17 years deep, the most recent figure standing at 448260.0% for Q1 2026.
- In Q1 2026, FCF Margin fell 44039856.0% year-over-year to 448260.0%; the TTM figure through Mar 2026 stood at 26127.14% (down 2383382.0% YoY), while the FY2025 annual figure was 13829.06%, down 1155418.0% from the prior year.
- FCF Margin for Q1 2026 stood at 448260.0%, down from 53905.79% in the prior quarter.
- The five-year high for FCF Margin was 803.66% in Q4 2023, with the low at 448260.0% in Q1 2026.
- The 5-year median for FCF Margin is 6994.62% (2025), against an average of 37634.8%.
- The sharpest annual moves came in 2025 and 2026: FCF Margin surged 1840907 bps in 2025, then slumped 44039856 bps in 2026.
- Celldex Therapeutics' FCF Margin stood at 1363.73% in 2022, then soared by 41 bps to 803.66% in 2023, then tumbled by 252 bps to 2828.26% in 2024, then tumbled by 1806 bps to 53905.79% in 2025, then plunged by 732 bps to 448260.0% in 2026.
- Business Quant data shows CLDX's FCF Margin at 448260.0% in Q1 2026, 53905.79% in Q4 2025, and 6127.81% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn | -275,359.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -275,359.09% |
| Mar 31, 2026 | -448,260.00% |
| Dec 31, 2025 | -53,901.65% |
| Jun 30, 2025 | -6,127.81% |
| Mar 31, 2025 | -7,861.44% |
| Dec 31, 2024 | -2,828.26% |
| Sep 30, 2024 | -1,751.24% |
| Jun 30, 2024 | -1,184.99% |
| Mar 31, 2024 | -26,270.51% |
| Dec 31, 2023 | -803.66% |
| Sep 30, 2023 | -1,262.36% |
| Jun 30, 2023 | -10,300.75% |
| Mar 31, 2023 | -3,014.89% |
| Dec 31, 2022 | -1,363.73% |
| Sep 30, 2022 | -8,731.45% |
| Jun 30, 2022 | -14,059.51% |
| Mar 31, 2022 | -14,430.46% |
| Dec 31, 2021 | -4,454.19% |
| Sep 30, 2021 | -10,821.57% |
| Jun 30, 2021 | -346.93% |